BioSpace News Archive

GenMark Diagnostics, Inc. announced the closing of its previously announced underwritten public offering of 8,341,968 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares, at the public offering price of $9.65 per share.

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2020.

Surgery Partners, Inc., a leading short-stay surgical facility owner and operator, announced results for the first quarter ended March 31, 2020.

Harrow Health, Inc. reported results for the first quarter 2020. Please click here to review Harrow Health’s Letter to Stockholders for the first quarter 2020.

Survey of 200+ melanoma survivors conducted prior to and during COVID-19 demonstrated increased anxiety around skin self-examination during COVID-19 due to lack of in-person physician access

BiomX Inc. (the “Company”) (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, May 14, 2020, at 8:00 a.m. ET to report first quarter 2020 financial results and provide a corporate update.

1Life Healthcare, Inc. (One Medical) (Nasdaq: ONEM) today announced that Amir Dan Rubin, Chair & CEO, and Bjorn Thaler, CFO, will participate in the following upcoming investor conference:

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced the Company will participate in a virtual fireside chat with BTIG.

Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the first quarter of 2020.

During COVID-19, the U.S. Food and Drug Administration will continue to utilize and implement additional alternative inspection tools and approaches while postponing domestic and foreign routine surveillance inspections.